Enliven Therapeutics, Inc. (NASDAQ:ELVN) Receives $41.20 Average Target Price from Analysts

Enliven Therapeutics, Inc. (NASDAQ:ELVN) has been given a consensus rating of “Moderate Buy” by the six analysts that are covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $41.20.

A number of research firms have weighed in on ELVN. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 15th.

Insider Buying and Selling at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 12,500 shares of the stock in a transaction that occurred on Wednesday, November 19th. The shares were sold at an average price of $22.33, for a total transaction of $279,125.00. Following the completion of the sale, the insider directly owned 902,688 shares of the company’s stock, valued at $20,157,023.04. This represents a 1.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Anish Patel sold 6,663 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, December 8th. The stock was sold at an average price of $21.02, for a total transaction of $140,056.26. Following the completion of the transaction, the chief operating officer owned 263,311 shares in the company, valued at approximately $5,534,797.22. This trade represents a 2.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 98,247 shares of company stock valued at $2,043,650 over the last 90 days. Insiders own 25.90% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several large investors have recently modified their holdings of ELVN. Quantbot Technologies LP acquired a new stake in shares of Enliven Therapeutics during the first quarter worth $60,000. BNP Paribas Financial Markets increased its stake in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. AlphaQuest LLC purchased a new position in Enliven Therapeutics in the 3rd quarter worth about $96,000. Tower Research Capital LLC TRC raised its holdings in Enliven Therapeutics by 194.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,286 shares of the company’s stock worth $106,000 after buying an additional 3,490 shares during the period. Finally, KLP Kapitalforvaltning AS lifted its stake in Enliven Therapeutics by 58.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,800 shares of the company’s stock valued at $136,000 after buying an additional 2,500 shares in the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Trading Up 3.5%

Enliven Therapeutics stock opened at $20.17 on Monday. Enliven Therapeutics has a 52 week low of $13.30 and a 52 week high of $25.37. The stock has a market cap of $1.20 billion, a price-to-earnings ratio of -10.96 and a beta of 0.35. The company’s 50-day moving average price is $20.86 and its two-hundred day moving average price is $20.43.

Enliven Therapeutics (NASDAQ:ELVN) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.43) by $0.11. Research analysts expect that Enliven Therapeutics will post -1.95 earnings per share for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.